Robert Flamini

Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial

Orrin Devinsky, Eric D. Marsh, Daniel J. Friedman et al. · The Lancet Neurology · 2015 · 890 citations

Cannabis Use, Psychotropic Medication, Neuropharmacology +5

Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial

Elizabeth A. Thiele, Eric D. Marsh, Jacqueline A. French et al. · The Lancet · 2018 · 868 citations

Placebo-controlled Phase 3, Neuropharmacology, Pharmacotherapy +4

<i>KCNQ2</i> encephalopathy

J Gordon Millichap, Kristen Park, Tammy N. Tsuchida et al. · Neurology Genetics · 2016 · 234 citations · Full text

Open-label use of highly purified CBD (Epidiolex®) in patients with CDKL5 deficiency disorder and Aicardi, Dup15q, and Doose syndromes

Orrin Devinsky, Chloe Verducci, Elizabeth A. Thiele et al. · Epilepsy & Behavior · 2018 · 183 citations · Full text

Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results

Linda Laux, E. Martina Bebin, Daniel Checketts et al. · Epilepsy Research · 2019 · 173 citations · Full text